Key Takeaways for Amgen Stock as of July 2026
- Thirty-four analysts cover Amgen stock, split between 10 buys, 4 outperforms, 17 holds, 1 underperform and 2 sells, with a $356 mean target sitting just 2% below where shares trade.
- TIKR’s mid case model prices Amgen stock at $467 by December 2030, a 29% total return running at 6% annualized.
- With normalized EPS set to trough at $5.60 next quarter before reaccelerating to 9.8% growth by December, the stock’s 98% target-to-price ratio hasn’t caught up to that turn.
- On July 1, a federal judge blocked Colorado’s price cap on Enbrel, protecting a franchise worth $2.23 billion in 2025 sales.
Amgen Stock Steadies as a Guidance Raise Meets a Legal Win on Enbrel
Amgen (AMGN) raised its full year 2026 guidance on April 30, lifting the revenue range to $37.1 billion to $38.5 billion and non-GAAP earnings per share to between $21.70 and $23.10, a day after reporting normalized EPS of $5.15 for the March quarter, up 5.1% year over year. Product sales grew 4% overall, and the six named growth drivers, Repatha, EVENITY, TEZSPIRE, oncology, rare disease and biosimilars, expanded 24% to $5.6 billion, or 70% of total sales.
CFO Peter Griffith tied that raise directly to the growth drivers on the Q1 call, saying, “These ranges reflect our confidence that the emerging growth drivers will more than offset the outgoing legacy brands.” Repatha carried much of that weight, growing 34% in the quarter as new-to-brand prescribing climbed 44% following updated primary prevention data from the VESALIUS-CV trial.
Amgen is also leaning on MariTide, its long-acting obesity antibody, to extend that growth trajectory past 2026. Management opened two new Phase III extension studies in April to test monthly, every-8-week and quarterly maintenance dosing, plus a separate SWITCH study moving patients off weekly GLP-1 injections onto MariTide.
That guidance held even as one of Amgen’s older drugs faced its own test. Chief Judge Daniel Domenico blocked Colorado’s first-of-its-kind price cap on Enbrel on July 1, ruling the state’s $31,200 annual cap would cause the company “significant and irreparable harm.” Enbrel generated $2.23 billion in 2025 sales, and the ruling removes, for now, a template other states had been watching.
Not every regulatory fight broke Amgen’s way. The FDA proposed withdrawing Tavneos in April after finding 76 cases of drug-induced liver injury, and the New England Journal of Medicine retracted the trial paper that supported the drug’s 2021 approval on June 29. Tavneos still posted $119 million in first quarter sales, up 32% year over year, but the drug faces a July 29 FDA hearing deadline that will decide its U.S. future.
Amgen is handling that scrutiny under a CFO in transition. Griffith is set to retire after guiding the 2026 raise, with Thomas Dittrich, a former Amgen chief accounting officer, taking the CFO seat on September 1.
Wall Street Keeps a Hold-Heavy Rating on Amgen Stock at a $356 Target
Wall Street holds a cautious but constructive rating on Amgen stock, with 10 buys and 4 outperforms outnumbered by 17 holds, 1 underperform and 2 sells across 34 covering analysts. The $356 mean target sits just 2% below where shares trade, a gap that has closed steadily since the $314 mean target recorded in June 2025.
Median targets moved in lockstep, rising from $318 to $355 over the same four quarters, while the high estimate has held near $427 since March 2026. That convergence between price and target has built through the same window in which the Colorado ruling removed one tail risk analysts had been pricing into Enbrel.
Wall Street Expects Amgen Stock’s Normalized EPS to Trough Before a 10% Rebound
Amgen stock’s normalized EPS grew 5.1% year over year to $5.15 in the quarter ended March 2026, extending a streak of modest but positive growth. Consensus estimates model a reversal in the June quarter, with normalized EPS falling 6.9% to $5.60 before the metric turns higher again.
That reversal accelerates through the back half of the year. Normalized EPS is estimated to grow 2.0% in the September quarter and 9.8% in the December quarter to $5.81, then settle near 4% for the first two quarters of 2027, at $5.37 and $5.84.
The September print becomes the threshold that confirms or breaks the setup: a return to growth validates the trough thesis, while another decline pushes the reacceleration into 2027.
TIKR Values Amgen Stock at $467, Pricing In the EPS Reacceleration
TIKR’s mid case model values Amgen stock at $467 by December 2030, a 29% total return from the current price of $363, or 6% annualized over 4.5 years.
That annualized pace lands below the double-digit returns growth investors typically chase, positioning Amgen stock closer to a steady compounder than a re-rating story.
The case rests on dynamics already in motion: growth drivers covering 70% of sales, a guidance raise built on that mix, and a legal win that locked in Enbrel’s cash flow near term. The model assumes normalized EPS carries through its modeled reacceleration to 9.8% growth by December, the same trend already showing up in the April guidance raise.
Should You Invest in Amgen Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Amgen Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Amgen Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze AMGN stock on TIKR for Free →
Looking for New Opportunities?
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
#Adessonews seleziona nella rete articoli di particolare interesse.
Se vuoi leggere l’articolo completo clicca sul seguente link
Gian Estrada
Source link
